Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells

Trial Profile

Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Haematological malignancies; Sickle cell anaemia; Thalassaemia
  • Focus Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 15 Sep 2016 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
    • 19 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov.
    • 19 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top